Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares in the company, valued at approximately $5,773,187.44. This represents a 2.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Robert Barrow also recently made the following trade(s):
- On Thursday, December 26th, Robert Barrow sold 19,106 shares of Mind Medicine (MindMed) stock. The shares were sold at an average price of $7.43, for a total value of $141,957.58.
Mind Medicine (MindMed) Stock Down 3.7 %
Shares of MNMD stock traded down $0.24 during mid-day trading on Friday, hitting $6.19. The stock had a trading volume of 1,096,667 shares, compared to its average volume of 1,426,184. The firm has a market capitalization of $466.53 million, a P/E ratio of -2.74 and a beta of 2.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. Mind Medicine has a 12-month low of $5.03 and a 12-month high of $12.22. The firm's 50-day moving average is $7.26 and its two-hundred day moving average is $6.97.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the prior year, the company posted ($0.59) EPS. On average, analysts predict that Mind Medicine will post -1.35 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on MNMD shares. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Oppenheimer reaffirmed an "outperform" rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 price target for the company. Robert W. Baird lowered their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. Finally, Chardan Capital started coverage on Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a "buy" rating and a $20.00 target price for the company. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $25.11.
View Our Latest Stock Analysis on MNMD
Hedge Funds Weigh In On Mind Medicine (MindMed)
A number of hedge funds and other institutional investors have recently modified their holdings of MNMD. Barclays PLC lifted its holdings in Mind Medicine (MindMed) by 203.6% during the third quarter. Barclays PLC now owns 136,098 shares of the company's stock worth $775,000 after buying an additional 91,271 shares during the period. Wellington Management Group LLP grew its stake in Mind Medicine (MindMed) by 142.6% in the third quarter. Wellington Management Group LLP now owns 185,722 shares of the company's stock valued at $1,057,000 after purchasing an additional 109,152 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Mind Medicine (MindMed) by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company's stock worth $9,548,000 after acquiring an additional 162,933 shares in the last quarter. SG Americas Securities LLC boosted its stake in Mind Medicine (MindMed) by 48.8% in the fourth quarter. SG Americas Securities LLC now owns 24,406 shares of the company's stock valued at $170,000 after acquiring an additional 8,004 shares in the last quarter. Finally, State Street Corp grew its holdings in Mind Medicine (MindMed) by 0.5% in the third quarter. State Street Corp now owns 1,814,829 shares of the company's stock worth $10,326,000 after purchasing an additional 9,782 shares during the last quarter. 27.91% of the stock is currently owned by institutional investors.
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Further Reading
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
